Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate for low bone mass in adults with chronic kidney disease
RBR-6vph3p2Phase 3Recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alendronate in osteoporosis, Metabolic osteopathies and chronic kidney disease (CKD) (4 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Started Jan 2024; status: recruiting.
02
Drugs
alendronate
03
Conditions
osteoporosisMetabolic osteopathieschronic kidney disease (CKD)
Beyond the preview
Go deeper on RBR-6vph3p2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6vph3p2.